脂肪乳治疗在重度羟氯喹过量中的应用——病例报告的叙述性综述
该叙述性综述系统检索PubMed、Embase.com、Cochrane CENTRAL、Web of Science Core Collection和Scopus,自建库至2023年11月1日,纳入16篇病例报告共18例接受脂肪乳治疗的羟氯喹中毒患者。脂肪乳治疗始终联合其他治疗,关于给药情形及推定效应的详细信息常缺乏;15/18患者存活出院,部分报告描述静脉脂肪乳后临床几乎立即改善,未报告明确不良反应。作者指出,依赖病例报告、报告细节程度不一、多数病例同时使用多种治疗药物难以将存活主要归因于脂肪乳、发表偏倚可能偏向成功结局,这些局限限制了对脂肪乳治疗羟氯喹中毒有效性的结论。
要点
- 16篇病例报告共18例接受脂肪乳治疗的羟氯喹中毒患者,15/18存活出院。
- 脂肪乳治疗始终联合其他治疗,关于静脉脂肪乳给药情形及推定效应的详细信息常缺乏。
- 部分报告描述静脉脂肪乳给药后临床几乎立即改善,未报告明确不良反应。
- 多数病例同时使用多种治疗药物,难以将存活主要归因于脂肪乳。
- 作者认为,偏倚风险、报告数量少及缺乏对有利和不良效应的系统报告,限制了对脂肪乳治疗羟氯喹中毒有效性的任何结论。
适用人群与场景
- 接受脂肪乳治疗羟氯喹中毒的患者(纳入标准:描述接受脂肪乳治疗羟氯喹毒性的原始观察性或干预性研究、病例系列和病例报告)
处置流程与药物剂量
- 静脉脂肪乳治疗作为羟氯喹中毒的治疗之一,在纳入的18例患者中均联合其他治疗使用。
研究设计与关键结果
- 研究类型:叙述性综述,系统检索PubMed、Embase.com、Cochrane Central Register of Controlled Trials (CENTRAL)/Wiley、Web of Science Core Collection/Clarivate Analytics和Scopus/Scopus.com,自建库至2023年11月1日,遵循PRISMA指南。
- 共识别157篇文章,16篇病例报告符合纳入标准,报告18例患者。
- 脂肪乳治疗始终联合其他治疗,关于静脉脂肪乳给药情形及其推定效应的详细信息常缺乏。
- 18例患者中15例存活出院。
- 部分报告描述静脉脂肪乳给药后临床几乎立即改善。
- 未报告明确的不良反应。
证据类型、等级与局限
- 证据类型:病例报告的叙述性综述。
- 局限:依赖病例报告,报告细节程度不一;多数病例同时使用多种治疗药物,难以将存活主要归因于脂肪乳;发表偏倚可能偏向成功结局;报告数量少;缺乏对有利和不良效应的系统报告。
对床旁实践的改变
- 作者认为,偏倚风险、报告数量少以及缺乏对有利和不良效应的系统报告,限制了对脂肪乳治疗羟氯喹中毒有效性的任何结论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Hydroxychloroquine has cardiac and cerebral sodium channel- and human ether-à-go-go-related gene (HERG) potassium channel-blocking effects. This causes depolarization delays, resulting in cardiovascular toxicity with potentially fatal consequences. Despite several supportive care options, hydroxychloroquine poisoning remains difficult to treat. Its high lipid solubility suggests that lipid emulsion therapy might be beneficial; however, no clear evidence regarding its efficacy is available. The aim of this review is to assess the evidence, the outcomes, and adverse events regarding the use of intravascular lipid emulsion therapy as a treatment for hydroxychloroquine poisoning.
METHODS: We conducted a systematic search in PubMed, Embase.com, Cochrane Central Register of Controlled Trials (CENTRAL)/Wiley, Web of Science Core Collection/Clarivate Analytics, and Scopus/Scopus.com from inception until 1 November 2023. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Inclusion criteria encompassed original observational or interventional studies, case series and case reports describing patients receiving lipid emulsion therapy for hydroxychloroquine toxicity. We extracted clinical data and performed a quality assessment of the included cases. We present the results as a narrative synthesis.
RESULTS: Of 157 identified articles, 16 case reports met the inclusion criteria, reporting on 18 patients. Lipid emulsion therapy was always associated with additional treatments, and detailed information on the circumstances regarding the administration of intravenous lipid emulsion and its presumed effect was often lacking. Fifteen of 18 patients survived to hospital discharge. Some reports described clear and almost immediate clinical improvement after intravenous lipid emulsion administration. No clear adverse effects were reported.
DISCUSSION: A limitation is the reliance on case reports, which varied in the degree of reported details. The administration of multiple therapeutic drugs in most cases made it difficult to attribute survival primarily to lipid emulsion. Publication bias may favour cases with successful outcomes.
CONCLUSION: Among published case reports, most patients who received lipid emulsion for treatment of hydroxychloroquine poisoning survived. The risk of bias, the small number of reports, and the lack of systematic reporting of both favourable and adverse effects limit any conclusions about the effectiveness of lipid emulsion for hydroxychloroquine poisoning.
参考来源
- Schieveen E, Gresnigt FMJ, den Haan C, et al. The use of lipid emulsion therapy in severe hydroxychloroquine overdose - a narrative review of case reports. Clin Toxicol (Phila). 2024. PMID: 39377146. doi:10.1080/15563650.2024.2407059
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。